Integrative clinico-molecular analysis reveals actionable subtypes and biomarkers in lung adenocarcinoma.

ABSTRACT: Deeper insights into omics in the clinical and tumor microenvironments of lung adenocarcinoma (LUAD) could reveal therapy-sensitive subtypes and novel treatments. From a cohort of 1008 samples from Chinese patients with LUAD with whole-genome and transcriptome sequencing data along with comprehensive longitudinal clinical and therapeutic information, we identified four prognostically distinct subtypes, namely, low proliferation and invasion (LPI), immune-desert (IMD), immune-enriched (IME), and high proliferation and invasion (HPI), based on the transcriptomic features linked to the radiological, pathological, and microenvironmental dimensions. Compared with chemotherapy, tyrosine kinase inhibitor (TKI) therapy demonstrated significantly superior efficacy for LPI and IMD, whereas no such d

SUBMITTER: Shang J 

PROVIDER: S-EPMC12852120 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature